A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator
Type 2 Diabetes Mellitus

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Type 2 diabetes, diabetes, diabetes mellitus, diabetes mellitus, type 2, non-TZD, thiazolidinedione, selective peroxisome proliferator-activated receptor gamma modulator, SPPARM, peroxisome proliferator-activated receptor gamma, PPAR gamma, insulin sensitizer, glucose control, endocrinopathy, hypoglycemic agent, sulfonylurea, metformin, pioglitazone, nutritional and metabolic diseases
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of Type 2 diabetes and on either sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy for at least 3 months at stable dose
- Males and Females (of non-childbearing potential or who are using dual barrier methods of contraception) between 30 and 75 years of age
- HbA1c must be ≥7.5% and ≤10% at screening
- Fasting Plasma Glucose must be <240 mg/dL at screening
Exclusion Criteria:
- History of type 1 diabetes
- History of diabetic ketoacidosis
- NYHA Class III or IV cardiac status or hospitalization for congestive heart failure within 6 weeks prior to Visit 1
- Treatment with any non-peroxisome proliferator-activated receptor (non-PPAR) antidiabetic agent, investigational or approved, other than metformin or permitted sulfonylureas within 3 months prior to screening
- Treatment with rosiglitazone, pioglitazone, or any PPAR investigational antidiabetic agent within 6 month prior to screening
- Body mass index >45 kg/m2
- Fasting triglycerides >500 mg/dL
- Uncontrolled hypertension (sitting systolic blood pressure >160 mmHg and/or sitting diastolic blood pressure >100 mmHg
- Presence of diabetic complications, which in the opinion of the investigator, would complicate the subject's participation in the study (i.e., require initiation of new medication)
Sites / Locations
- Northern California Research
- National Research Institute
- VA San Diego Healthcare System
- Apex Research Institute
- Internal Medicine of the Rockies
- Creekside Endocrine Associates, PC
- Clinical Research Consulting, LLC
- MedStar Research Institute
- Clinical Research of South Florida
- The Center for Diabetes and Endocrine Care
- Baptist Diabetes Associates, PA
- International Research Associates, LLC
- Elite Research Institute
- Suncoast Clinical Research, Inc.
- Suncoast Clinical Research, Inc.
- Meridien Research
- Meridien Research
- Clinical Research of Central Florida
- Executive Health and Research Associates, Inc.
- Endocrine Research Solutions, Inc.
- Cedar-Crosse Research Center
- ICCT Reseach International
- American Health Network
- L-Marc Research Center
- New Orleans Center for Clinical Research
- Stephen R. Smith, MD
- Olive Branch Family Medical Center
- Diabetes and Endocrinology Specialists, Inc.
- Saint Luke's Lipid and Diabetes Reseach Center
- Bozeman Deaconess Internal Medicine Associates
- Comprehensive Clinical Research
- Kaleida Health Diabetes Center
- UNC Diabetes Care Center/Highgate Specialty Center
- Fairbrook Medical Clinic
- Diabetes & Endrocrinology Consultants
- The Lindner Clinical Trial Center
- IVA Research
- Rapid Medical Research, Inc
- Opitmed Research, LTD
- ResEvo LLC
- Delaware Smith Clinic
- Prestige Clinical Research
- Wells Institute for Health Awareness
- Frederick C Smith Clinic
- Your Diabetes Endocrine Nutrition Group, LLC
- Clinical Research Source, Inc
- Tri-State Medical Group, Inc.
- Lycoming Internal Medicine, Inc.
- New England Center for Clinical Research
- Hartwell Research Group
- Medical Research South
- Palmetto Clinical Trial Services, LLC
- Dallas Diabetes and Endocrine Research Center
- Research Institute of Dallas
- Baylor University Endocrine Center
- Diabetes Center of the Southwest
- Quality Research, Inc.
- DGD Research
- Salem VA Medical Center R&D Office
- Nucleo Medico Vallarta
- Comite Mexicano para la Prevencion de la Osteoporosis A.C.
- Centro Especializado en Diabetes y Obisidad (EDOPEC)
- Instituto Nacional de Nutricion Salvador Zubiran (INNSZ)
- Instituto Mexicano de Investigacion Clinica
- Unidad Metabolica y Cardiovascular SC
- Hospital Santa Engracia
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Experimental
Experimental
Active Comparator
Placebo Comparator
INT131 besylate 0.5 mg
INT131 besylate 1 mg
INT131 besylate 2 mg
INT131 besylate 3 mg
pioglitazone HCl 45 mg
placebo
INT131 besylate 0.5 mg once-daily administration and matching placebo to pioglitazone HCl.
INT131 besylate 1 mg once-daily administration and matching placebo to pioglitazone HCl
INT131 besylate 2 mg administered once-daily and matching placebo to pioglitazone HCl
INT131 besylate 3 mg administered once-daily and matching placebo to pioglitazone HCl
pioglitazone HCl 45 mg administered once-daily and matching placebo to INT131 besylate
placebo administered once-daily, matching placebo to INT131 besylate and matching placebo to pioglitazone HCl